Development of new agents for the treatment of advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 3, 2003, Pages 154-164

  Lewis, Nancy L ^a   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; Epidermal growth factor receptor; Oxaliplatin; Predictive markers; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PELITINIB; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ARTERY THROMBOSIS; BONE MARROW TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; DYSESTHESIA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLICULITIS; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; LARYNX SPASM; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; RASH; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING;

EID: 0346339676     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.021     Document Type: Review

References (106)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998; 16:301-308.
3. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
4. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37:597-604.
5. Cunningham D, Pyrhonen S, James R et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouraciil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
6. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic · colorectal cancer. Lancet 1998; 352:1407-1412.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
9. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9:105-108.
10. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-2744.
11. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A:1280-1284.
12. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
13. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8:876-885.
14. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219.
15. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOL-FOX6). GERCOR. Eur J Cancer 1999; 35:1338-1342.
16. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:2950-2958.
17. Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II mized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
18. Clinical Studies: combination therapy with Eloxatin and infusional 5-FU/LV in previously treated patients with advanced colorectal cancer. Eloxatin™ (oxaliplatin for injection) [prescribing information]. New York: Sanofi-Synthelabo, 2002.
19. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
20. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
21. Goldberg RM, Morton RF, Sargent DJ et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
22. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35:1343-1347.
23. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (Abstract #494).
24. Beretta E, Bajetta E, DiBartolomeo M, et al. Combination of oxaliplatin (Oxa) and irinotecan (CPT11) in FU-resistant metastatic colorectal cancer (CRC). Proc Am Soc Clin-Oncol 2002; 21:165a (Abstract #657).
25. Kemeny NE, Tong WP, Gonen M, et al. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Annals of Oncology 2002; 13: 1490-1496.
26. Salud A, Saigi E, Cirera L, et al. Phase II trial of irinotecan and oxaliplatin in 5-FU resistant advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:171a (Abstract#681).
27. Kretzschmar A, Thuss-Patience PC, Grothey A, et al. Weekly combination of oxaliplatin (Ox) and irinotecan (Iri) in 5-FU resistant metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001; 20:136a (Abstract #540).
28. Kaechele V, Hartmann JT, Lutz MP, et al. A phase II study of dose-dense irinotecan and oxaliplatin as 2nd line treatment in advanced colorectal cancer after pretreatment with 5-FU. Proc Am Soc Clin Oncol 2002; 21:110b (Abstract #2252).
29. Jordan K, Kellner O, Constantin C, et al. Randomized phase II trial of capecitabine plus irinotecan vs. capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): results of an interim analysis. Proc Am Soc Clin Oncol 2002; 21:103b (Abstract #2225).
30. Cassata A, Stani SC, Alu M, et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001; 20:144a (Abstract #573).
31. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
32. Shields AF, Zalupski MM, Marshall JL, et al. A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:143a (Abstract #568).
33. Scheithauer W, Kornek GV, Raderer M, et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002; 13:1583-1589.
34. Tabernero J, Cassidy J, Conroy, T, et al. Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients with metastatic colorectal cancer (MCRC): results of an international multicentre phase II trial. Proc Amer Soc Clin Oncol 2002; 21:133a (Abstract #531).
35. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37:285-289.
36. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-225.
37. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
38. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103:273-282.
39. Radinsky R, Risin, Fan, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1:19-31.
40. Solic N, Davies DE. Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells. Exp Cell Res 1997; 234:465-476.
41. Damstrup L, Kuwada SK, Dempsey PJ, et al. Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 1999; 80:1012-1019.
42. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
43. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995; 14:323-338.
44. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991; 9:553-562.
45. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 1992; 13:125-131.
46. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5:909-916.
47. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
48. Saltz LB, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225(Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGPR). Proc Am Soc Clin Oncol 2002; 21:127a (Abstract #504).
49. Saltz LB, Rubin M, Hochster H. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
50. Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGF4-positive tumors. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1862).
51. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002; 29:47-50.
52. Roskos L, Lohner M, Osborn K, et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients. Proc Am Soc Clin Oncol 2002; 21:91a (Abstract #362).
53. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
54. Figlin R, Crawford J, Lohner M, et al. ABX - EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody (Mab) in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #35).
55. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60(suppl 1):25-32.
56. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
57. Hammond LA, Figueroa J, Schwartzberg L, et al. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:137a (Abstract #544).
58. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
59. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
60. Hidalgo M, Mallik S, Rowinsky EK, et al. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 2001; 20:71a (Abstract #281).
61. Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvI-II transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 2002; 21:21a (Abstract #79).
62. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
63. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
64. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
65. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
66. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000 6:2803-2807.
67. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53:4727-4735.
68. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-1364.
69. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78:1379-1384.
70. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4:1279-1285.
71. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
72. Kanno S, Oda N, Abe M, et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19:2138-2146.
73. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
74. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93:14765-14770.
75. Sledge G, Miller K, Novotny WF, et al. A phase II trial of single-agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:3a (Abstract #5C).
76. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
77. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRQ: Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Presented at: The American Society of Clinical Oncology 2003; 22: (Abstract #3646). Available at: http://www.asco.org/hurwitz_no3646. Accessed on: Nov. 13, 2003.
78. Giantonio B, Levy D, O'Dwyer P, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (adv CRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc Am Soc Clin 2003; 22:255 (Abstract #1024).
79. Williams C, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer. Ann N Y Acad Sci 1999; 889:72-83.
80. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282:1254-1257.
81. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120.
82. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60:5599-5602.
83. Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001; 61:3961-3968.
84. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2:544-551.
85. Elder DJ, Halton DE, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3:1679-1683.
86. Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997; 113:1883-1891.
87. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
88. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectai cancer: a population-based study. Arch Intern Med 1999; 159:161-166.
89. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333:609-614.
90. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316.
91. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80:1618-1619.
92. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
93. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt) 2002; 16(4 suppl 3):17-21.
94. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-3229.
95. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376.
96. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
97. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47.
98. Gagne IF, Montminy V, Belanger P et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.
99. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 2002; 62:446-450.
100. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
101. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer2001; 85:827-830.
102. Etienne MC, Chazal M, Laurent-Puig P, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002; 20:2832-2843.
103. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-942.
104. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21:3075-3079.
105. Park DJ, Stoehlmacher J, Zhang W, et al. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61:8654-8658.
106. Lenz HJ, Park DJ, Zhang W, et al. A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:129a (Abstract #513).